Fig 1.
2L: second-line; CT: chemotherapy; dx: diagnosis; IO: immunotherapy; NSCLC: non-small cell lung cancer; VA: Veterans Affairs.
Table 1.
Patient demographic and clinical characteristics by 2L treatment.
Table 2.
Multivariable logistic regression to assess association between patient characteristics and receipt of 2L IO vs CT.
Fig 2.
Kaplan–Meier plot of OS for patients who received 2L IO vs CT, from initiation of 2L therapy.
2L: second-line; CI: confidence interval; CT: chemotherapy; Est: estimated; HR: hazard ratio; IO: immunotherapy; OS: overall survival; Tx: treatment.
Table 3.
Inverse probability weighting Cox proportional hazard regression to evaluate the effect of treatment on OS.
Table 4.
Summary of HCRU in 2L patients.
Table 5.
AE occurrence by 2L treatment.